Re: And by the way....in year 2018-2019
If company doesn't have ability to put drug on the market, then sell the company is better choice. $3 per share is a joke now no matter what!
SESN never had that thought too, but changed it recently. SESN still needs to run another phase 3 trial (requested by FDA) to prove it's drug works well. But that news immediately put stock up 30% in that day. And market cap is close to CRMD now. Roche could buy SESN. How about CRMD? I thought CRMD's HQ office is in Novartis's building?